Esketamine Gets FDA Approval
The Carlat Psychiatry Report, Volume 17, Number 6&7, June 2019
Michael Posternak, MD.
Psychiatrist in private practice, Boston, MA.
Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
On March 5, 2019, the FDA approved esketamine (Spravato) nasal spray as add-on therapy to traditional antidepressant medications for treatment-resistant depression (TRD). In this article, I will describe the events that led to esketamine’s development, review the data submitted to the FDA, and discuss what the future might hold for esketamine.